A California-based biotech company stirred things up on Wednesday after it was announced the publication of preclinical data on its lead clinical compound, LB-100.

To read the full story on AllPennyStocks.com, click here.

Lixte Biotechnology (NASDAQ:LIXTW)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Lixte Biotechnology.
Lixte Biotechnology (NASDAQ:LIXTW)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Lixte Biotechnology.